With Less Than 90 Minutes To Go, (NYSE AMERICAN: VNRX) Is Back At The Top Of Our Screen — With A Float Under 12M Shares

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Up Next: VolitionRx Limited (NYSE American: VNRX) Is In Focus This Morning—Wednesday, August 26, 2026… Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up (VNRX) While It’s Still Early… August 26, 2026 Dear Reader, With less than 90 minutes to go before the opening bell, VolitionRx Limited (NYSE American: VNRX) is back at the top of our screen this morning. Between its recent peer-reviewed Capture-Seq data, expanding diagnostic pipeline, and multiple active licensing discussions, there is plenty here worth understanding before the session gets underway. A multi-national epigenetics company just published the first peer-reviewed paper on a technology that isolates over 99% pure cancer-derived DNA from a standard blood draw — a feat no other company has publicly demonstrated. The name is VolitionRx Limited (NYSE American: VNRX), and it is topping our watchlist this morning—Wednesday, August 26, 2026. Early this month, Volition announced the publication of its Capture-Seq liquid biopsy paper in the peer-reviewed journal Clinical Epigenetics. The technology addresses what the company describes as the biggest problem facing liquid biopsy worldwide: the vast majority of circulating DNA in plasma comes from healthy cells, not cancer cells. Volition's approach produces virtually pure tumor-derived DNA — creating what amounts to a new class of biomarker for cancer detection and monitoring. Then, one week later on August 12, 2026, the company announced that its rapid finger-prick prototype for sepsis detection showed a Spearman correlation of 0.85 and a Pearson correlation of 0.881 against its established CE-marked Nu.Q NETs laboratory test — results strong enough to suggest the point-of-care format could be used to triage high-risk patients directly in the ER or at the bedside. On August 13, 2026, Volition reported its Q2 2026 results: first-half revenue reached $1.4M, a 112% increase over the same period in 2025. Operating expenses fell 32% year over year, and the operating loss declined 34% to $4.2M for the quarter. The company is actively engaged in technical evaluations and licensing discussions with more than a dozen of the world's leading diagnostic and liquid biopsy firms. Here's what has us watching VNRX this morning — Wednesday, August 26, 2026. Keep in mind, VNRX has less than 12M shares listed as available to the public right now. The company currently has analyst coverage from names including Michael Okunewitch of Maxim Group, Justin Walsh of Jones Research, Yi Chen of H.C. Wainwright, Jason Kolbert of D. Boral Capital, and Bruce Jackson of Benchmark. Published targets tracked across the analyst group currently range from approximately $2 to $24 per share, which suggests significant upside potential from where VNRX is currently trending as the company advances its diagnostic platforms and licensing strategy. That combination — a peer-reviewed liquid biopsy breakthrough, a working point-of-care sepsis prototype, growing revenue, and licensing discussions with global diagnostic leaders — is exactly why VNRX belongs on the watchlist right now. Before we walk through the recent developments, here's the foundation readers need to understand first. About VolitionRx VolitionRx Limited is a multi-national epigenetics company headquartered in Henderson, Nevada, with operations across Europe and the United States. Through its subsidiaries, Volition develops and commercializes blood-based diagnostic, prognostic, and disease-monitoring tests spanning oncology, veterinary medicine, sepsis, and infectious disease. The company operates across five core technology pillars. Nu.Q Vet is an affordable blood test for cancer detection in dogs, commercialized through a partnership with Heska, with a feline lymphoma test now under peer review. Nu.Q NETs is a CE-marked diagnostic for detecting Neutrophil Extracellular Traps, applicable across sepsis, trauma, and a range of acute and chronic diseases. Nu.Q Cancer is a prognostic assay for lung cancer patients currently being prepared for reimbursement submission in France. Capture-Seq is the company's proprietary liquid biopsy technology for multi-cancer early detection. And Nu.Q Discover is a research services platform providing nucleosome profiling to pharma and biotech clients. Volition's business model is built around licensing its proprietary tests to large, established diagnostic companies with global distribution infrastructure. CEO Cameron Reynolds described the approach during the Q2 2026 earnings call: the company is pursuing arrangements structured around upfront milestone payments, royalties, and recurring revenue. As of August 2026, Volition is in active discussions with more than 12 leading diagnostic and liquid biopsy companies at various stages of technical evaluation and negotiation. Revenue for the full year 2025 came in at $1.7M, up from $1.2M in 2024. First-half 2026 revenue has already reached $1.4M, driven by a Q1 surge to $1.0M that represented 300% growth year over year and beat consensus estimates by 126%. Operating expenses have been cut meaningfully — total Q2 2026 opex dropped to approximately $4.6M from $6.7M a year earlier, aided by a 27% reduction in headcount. The company currently employs approximately 75 people and ended Q1 2026 with $3.1M in cash. During Q2, Volition raised $5.3M in net proceeds — $1.2M through its at-the-market facility and $4.1M from a confidentially marketed public offering of shares and warrants. Where VNRX Fits in a $27B+ Addressable Market Volition sits at the intersection of two large and rapidly expanding diagnostic categories: liquid biopsy and point-of-care testing. The global liquid biopsy market was valued at approximately $6.4B in 2025 and is projected to surpass $36B by 2035, expanding at a compound annual growth rate of over 19%. The field is being propelled by growing adoption of non-invasive cancer diagnostics, precision oncology initiatives, and increasing payer acceptance of genomic-based testing. Guardant Health, Roche, and Illumina currently lead the space, but the market remains fragmented enough that differentiated technologies can carve out meaningful positions — particularly in areas where current methods face sensitivity limitations. Volition's Capture-Seq technology is designed to solve a specific technical bottleneck: the challenge of separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA in blood plasma. The company reports that its method produces over 95% sensitivity for Stage I and Stage II cancers at 95% specificity in a blinded validation cohort — figures that, if replicable at scale, would position the technology competitively against next-generation sequencing approaches that currently dominate the ctDNA analysis landscape. Management estimates the combined total addressable market across all Volition pillars at more than $27B on an annualized basis: approximately $23B for multi-cancer early detection via Capture-Seq, approximately $3.8B for NETosis-related diagnostics, and additional addressable segments across veterinary cancer testing and minimal residual disease monitoring. Meanwhile, the sepsis diagnostics market adds another dimension. Volition's Nu.Q NETs assay already holds a CE Mark for use across 27 European countries, and the company is now part of the DETECSEPS program — a $7.3M French government-backed study evaluating early sepsis detection in real-world settings. The recent finger-prick prototype data expands the addressable market beyond centralized lab testing and into emergency departments, physician offices, and markets with less developed laboratory infrastructure. VNRX's 2026 Timeline: Earnings, Prototypes, Patents, and Partnerships August 13, 2026 — Volition reported Q2 2026 financial results: first-half revenue of $1.4M (up 112% YoY), with operating expenses down 32% and operating loss reduced 34% to $4.2M. Confirmed licensing discussions with 12+ global diagnostic firms. Installing an IDS i10 automated analyzer at the Mayo Clinic for trauma patient model development. August 12, 2026 — Demonstrated that its rapid lateral flow finger-prick prototype is highly correlated (Spearman: 0.85, Pearson: 0.881) with the established Nu.Q NETs laboratory test in critically ill sepsis patients. Part of the SUMMIT research program. August 5, 2026 — Published the first peer-reviewed paper on its Capture-Seq liquid biopsy technology in Clinical Epigenetics, demonstrating the isolation and analysis of over 99% pure circulating tumor-derived DNA. July 7, 2026 — Released a clinical study demonstrating the prognostic value of Nu.Q Cancer in newly diagnosed lung cancer patients, prepared with researchers at France's second-largest university hospital system, the Hospices Civils de Lyon. June 17, 2026 — Announced a collaboration with Sysmex Corporation, a global leader in in vitro diagnostics (TYO: 6869), to optimize Nu.Q NETs on Sysmex's platform. Confirmed successful transfer of the assay and commencement of the optimization phase. June 3, 2026 — Filed a strategic patent covering the use of Nu.Q NETs for Ebola virus triage and treatment monitoring, expanding the IP portfolio across infectious disease applications. May 6, 2026 — Submitted a clinical manuscript reporting 86% lymphoma detection at 97% specificity using its Nu.Q Vet feline prototype assay. Publication is expected to trigger a $5M contractual milestone payment. 8 Reasons Why VNRX Is At The Top Of Our Watchlist This Morning—Wednesday, August 26, 2026… 1. Low Float: with fewer than 12M shares listed as available to the public, VNRX’s small float could have the potential to witness big moves if demand begins to shift. 2. Peer Reviewed: after publishing the first peer-reviewed paper on Capture-Seq, VNRX now has published data showing isolation and analysis of more than 99% pure circulating tumor-derived DNA. 3. Revenue Growth: with first-half 2026 revenue reaching $1.4M, VNRX reported a 112% increase compared with the same period in 2025. 4. Licensing Talks: with more than 12 leading diagnostic and liquid biopsy companies in technical evaluations or licensing discussions, VNRX is actively pursuing broader commercialization pathways. 5. Early Detection: in a blinded validation cohort, VNRX reported more than 95% sensitivity for Stage I and Stage II cancers at 95% specificity using its Capture-Seq technology. 6. Point-of-Care Data: after reporting Spearman correlation of 0.85 and Pearson correlation of 0.881 for its finger-prick prototype, VNRX showed strong alignment with its established Nu.Q NETs laboratory test in critically ill sepsis patients. 7. Multiple Potential Catalysts: with recent developments spanning Capture-Seq, Nu.Q NETs, Sysmex, Mayo Clinic, Nu.Q Cancer, and Nu.Q Vet, VNRX has several active programs giving researchers multiple areas to track. 8. Analyst Coverage: with multiple analysts currently covering the company and published targets ranging from approximately $2.00 to $24.00, VNRX has outside research coverage spanning a wide range of expectations. Pull Up (VNRX) While It’s Still Early… When we step back and look at the bigger picture, it's easy to see why VNRX has landed on our radar. This is a company that just published a peer-reviewed liquid biopsy breakthrough, demonstrated a working finger-prick sepsis prototype, and is reporting 112% first-half revenue growth — all while cutting operating expenses by 32% and actively negotiating with more than a dozen global diagnostic leaders. The combined addressable market across all Volition pillars exceeds $27B annually, and the company is positioned to enter routine clinical use for lung cancer diagnostics in France by year-end 2026. Whether your focus is early-stage diagnostics, epigenetics, or companies operating across $27B+ in combined addressable markets, VNRX is one to watch. We have all eyes on VNRX this morning. Take a look at VNRX while it’s still early. Also, keep a look out for my next update, it could be coming any moment. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 08/25/2026 and ending on 08/26/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, Goldwyn Media LLC has paid TD Media LLC fifty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid six hundred sixty five thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/vnrx-8y40C/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe About our service provider Sent by jeff@stocknewstrends.com

A Proposed Merger And Tiny Float Taps (Nasdaq: SMTK) For Our #1 Watchlist Spot

First, a quick recap.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored A Proposed Merger And Tiny Float Taps (Nasdaq: SMTK) For Our #1 Watchlist Spot SMTK's Float Now Stands Below 1Mn Shares *Click Here To Get Our Alerts Faster Via SMS* August 26th Greetings Readers, First, a quick recap. Tuesday's profile went on a tear. Following an early pullback after the bell, it caught the surge bug and popped from a low of $8.76 to a high of $11.66. That nearly $3.00 run resulted in a move of approximately 33% intraday. Now, here's what we're watching next... Most companies spend years searching for commercial traction. Smartkem, Inc. (Nasdaq: SMTK) found it first in organic semiconductor materials, then began reaching outward, into critical minerals. The result is a company now touching two of the most strategically sensitive supply chains in the global economy, all at once. Then, this happened: Earlier this month, Smartkem made a game-changing announcement that they are planning to combine with Ferrox Critical Minerals, a British Virgin Islands-registered entity developing the Tivani Deposit in South Africa This follows the company's July 27th Form 8-K that confirmed SMTK extended a $4.5Mn convertible bridge loan to Ferrox Critical Minerals. The loan carries a 5% annual interest rate, matures January 31st, 2027, and includes a $400K origination fee. More notably, Smartkem secured exclusive transaction rights over Ferrox through December 31st, 2026, alongside broad rights of first refusal on all major corporate decisions by Ferrox. In June 2026, the company extended a $2.5Mn convertible bridge loan under similar terms. According to Ferrox Critical Minerals, the deposit contains an estimated 471 million tonnes of NI 43-101-compliant titaniferous magnetite resource, with the potential for an additional 1.0 to 1.5Bn additional tonnes pending extension negotiations. The backdrop for these moves is a global critical minerals market in the early stages of structural strain. According to the IEA's Global Critical Minerals Outlook 2026, base metals including aluminum, copper, and tin rose by approximately 1/3 between January 2025 and April 2026, with copper reaching record highs. Lithium prices more than doubled. China's rare earth export controls placed an estimated $6.5Tn annually in downstream manufacturing outside China in a precarious position. In that environment, companies with credible access to secure, non-Chinese mineral supply chains are drawing a different kind of attention from market watchers. Beyond critical minerals, SMTK has been building its capital foundation in parallel. In June and July 2026, the company completed multiple closings under its Series A Preferred St-ock Purchase Agreement, raising approximately $7.0Mn in new capital through preferred shares and warrants. This is part of a broader $17.1Mn preferred st-ock and warrant program, according to the company's SEC filings. And following a recent share structure change, SMTK now has a very low float of fewer than 1Mn shares according to Yahoo Finance. About Smartkem, Inc. (Nasdaq: SMTK) Smartkem, Inc. develops and manufactures advanced electronic materials for next-generation applications. The company's flagship TRUFLEX(R) platform consists of organic semiconductor and dielectric inks, or liquid electronic polymers, that integrate into existing manufacturing processes at low temperatures. The technology enables organic thin-film transistor backplanes used in MicroLED displays, flexible biometric sensors, and wearable electronics. Founded in the UK, Smartkem operates research and development facilities in Manchester, and a US corporate address in Wilmington, Delaware. 5 Potential Catalysts For (Nasdaq: SMTK) Put It At The Top Of Our Watchlist #1. A Low Float Creates The Potential For Significant Volatility. Yahoo Finance is reporting that SMTK has a float of roughly 546.88k shares. With a float this size, there could be a strong potential for heightened volatility on any given day. #2. Ferrox's 471Mn-Tonne Titaniferous Magnetite Deposit Is Drawing Strategic Capital Into SMTK. The Tivani Project holds a NI 43-101-compliant resource of an estimated 471Mn tonnes, targeting titanium dioxide slag, pig iron, and vanadium pentoxide production. Ferrox has a fully-granted Mining Right dating to December 2013 and is targeting initial production in 2027. SMTK's proposed merger with Ferrox creates an interesting scenario for the company. #3. The Defense Production Act Could Create A Potential Boon. The federal government invoked the Defense Production Act on recoverable critical minerals on July 30th, 2026, which is the sector Ferrox occupies. This puts SMTK in the middle of America’s accelerated pursuit of supply chain security. #4. China's Export Controls Are Rewriting the Global Critical Minerals Playbook, and SMTK Is Positioned Along That Fault Line. The IEA reports that China's rare earth and graphite export restrictions have placed an estimated $6.5Tn annually in downstream manufacturing outside China at risk. Tungsten prices surged approximately 500% in the period covered by the IEA's 2026 outlook. As Western governments direct approximately $65Bn in public finance toward domestic critical mineral supply chains, companies like SMTK with early exposure to alternative supply routes may attract heightened scrutiny from institutional and retail market watchers alike. #5. There Were Several Oversold Leaning Technicals At Tuesday's Close. Over at Barchart, the website reported that both of SMTK's 9-Day and 14-Day Relative Strength Indices were below 28% at close on Tuesday. Additionally, the site shared that SMTK's 14-Day Raw Stochastic was below 6%. These technicals lean towards oversold levels and suggest a healthy reversal could potentially be nearing. In Closing... Smartkem, Inc. (Nasdaq: SMTK) is not chasing a trend. It's executing a deliberate repositioning across two verticals that each carry structural demand characteristics: semiconductor materials and critical minerals. The proposed Ferrox merger gives SMTK a potential gateway into one of southern Africa's most significant undeveloped mineral deposits. Its TRUFLEX(R) materials continue generating commercial traction with some of the world's largest electronics manufacturers. What makes SMTK worth monitoring is the combination of scope and timing. Critical minerals are becoming a national security priority. Advanced semiconductor materials are increasingly vital in next-generation wearable and display technologies. Coverage is underway on Smartkem, Inc. (Nasdaq: SMTK). Updates will be available soon. Keep your eyes peeled.  Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/26/2026 and ending on 08/26/2026 to publicly disseminate information about (SMTK:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (SMTK:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/smtk-vel4u/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice

(Nasdaq: SMTK) Surges Up Our Watchlist With A Proposed Merger In The Spotlight

We've got a new Nasdaq profile at the top of our watchlist.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: SMTK) Surges Up Our Watchlist With A Proposed Merger In The Spotlight A Float Of Fewer Than 1Mn Shares Means There Could Be A Strong Potential For Heightened Volatility *Get Our Updates Faster—Tap Here To Receive SMS Alerts* August 26th Greetings, Friend! Up and at 'em Tuesday morning? If not, you may have missed an explosive mover. Our most recent low float idea put together a solid surge during the day after swinging from an early low of $8.76 to a high of $11.66. Popping nearly $3.00 in a short span of time, that profile ran approx. 33% intraday. Now, we're tracking a another watchlist-worthy idea.  Most companies spend years searching for commercial traction. Smartkem, Inc. (Nasdaq: SMTK) found it first in organic semiconductor materials, then began reaching outward, into critical minerals. The result is a company now touching two of the most strategically sensitive supply chains in the global economy, all at once. Then came August and a major announcement: Just a handful of weeks ago, Smartkem hits the headlines with a key news announcement that they are planning to combine with Ferrox Critical Minerals, a British Virgin Islands-registered entity developing the Tivani Deposit in South Africa This follows the company's July 27th Form 8-K that confirmed SMTK extended a $4.5Mn convertible bridge loan to Ferrox Critical Minerals. The loan carries a 5% annual interest rate, matures January 31st, 2027, and includes a $400K origination fee. More notably, Smartkem secured exclusive transaction rights over Ferrox through December 31st, 2026, alongside broad rights of first refusal on all major corporate decisions by Ferrox. That was not the first time Smartkem has backed Ferrox. In June 2026, the company extended a $2.5Mn convertible bridge loan under similar terms. According to Ferrox Critical Minerals, the deposit contains an estimated 471 million tonnes of NI 43-101-compliant titaniferous magnetite resource, with the potential for an additional 1.0 to 1.5Bn additional tonnes pending extension negotiations. The backdrop for these moves is a global critical minerals market in the early stages of structural strain. According to the IEA's Global Critical Minerals Outlook 2026, base metals including aluminum, copper, and tin rose by approximately 1/3 between January 2025 and April 2026, with copper reaching record highs. Lithium prices more than doubled. China's rare earth export controls placed an estimated $6.5Tn annually in downstream manufacturing outside China in a precarious position. In that environment, companies with credible access to secure, non-Chinese mineral supply chains are drawing a different kind of attention from market watchers. Beyond critical minerals, SMTK has been building its capital foundation in parallel. In June and July 2026, the company completed multiple closings under its Series A Preferred St-ock Purchase Agreement, raising approximately $7.0Mn in new capital through preferred shares and warrants. This is part of a broader $17.1Mn preferred st-ock and warrant program, according to the company's SEC filings. And following a recent share structure change, SMTK now has a very low float of fewer than 1Mn shares according to Yahoo Finance. Key Company Details About Smartkem, Inc. (Nasdaq: SMTK) Smartkem, Inc. develops and manufactures advanced electronic materials for next-generation applications. The company's flagship TRUFLEX(R) platform consists of organic semiconductor and dielectric inks, or liquid electronic polymers, that integrate into existing manufacturing processes at low temperatures. The technology enables organic thin-film transistor backplanes used in MicroLED displays, flexible biometric sensors, and wearable electronics. Founded in the UK, Smartkem operates research and development facilities in Manchester, and a US corporate address in Wilmington, Delaware. There Are 6 Potential Catalysts For (Nasdaq: SMTK) That Put This Profile Atop Our Watchlist Wednesday #1. An All-St-ock Merger Agreement With Ferrox Critical Minerals Announced. On August 3rd, 2026, SMTK signed a definitive business combination agreement to combine with Ferrox Critical Minerals in an all-st-ock transaction valued at $125Mn. This move aims to add the Tivani Project's iron, titanium, and vanadium assets in South Africa's Limpopo Province to SMTK's materials platform and position the combined entity as a vertically integrated electronics and critical minerals company. #2. At Fewer Than 1Mn Shares, This Profile Has A Very Low Float. Yahoo Finance reports that SMTK has a float of roughly 546.88k shares. When a profile comes with a float this size, there could be a strong potential for heightened volatility daily. #3. Ferrox's 471Mn-Tonne Titaniferous Magnetite Deposit Is Drawing Strategic Capital Into SMTK. The Tivani Project holds a NI 43-101-compliant resource of an estimated 471 million tonnes, targeting titanium dioxide slag, pig iron, and vanadium pentoxide production. Ferrox has a fully-granted Mining Right dating to December 2013 and is targeting initial production in 2027. SMTK's exclusive transaction rights through year-end 2026 position the company as the gatekeeper to this asset. #4. The Defense Production Act Could Create A Potential Boon. The federal government invoked the Defense Production Act on recoverable critical minerals on July 30th, 2026, which is the sector Ferrox occupies. This puts SMTK in the middle of America’s accelerated pursuit of supply chain security. #5. China's Export Controls Are Rewriting the Global Critical Minerals Playbook, and SMTK Is Positioned Along That Fault Line. The IEA reports that China's rare earth and graphite export restrictions have placed an estimated $6.5Tn annually in downstream manufacturing outside China at risk. Tungsten prices surged approximately 500% in the period covered by the IEA's 2026 outlook. As Western governments direct approximately $65Bn in public finance toward domestic critical mineral supply chains, companies like SMTK with early exposure to alternative supply routes may attract heightened scrutiny from institutional and retail market watchers alike. #6. Key Technical Indicators Are Trending Near Oversold Levels. At close on Tuesday, the Barchart website reported that both of SMTK's 9-Day and 14-Day Relative Strength Indices were below 28%. Furthermore, the site shared that SMTK's 14-Day Raw Stochastic was below 6%. These technical indicators are trending towards oversold levels and suggest a healthy reversal could be around the corner. Our Final Take Smartkem, Inc. (Nasdaq: SMTK) is not chasing a trend. It's executing a deliberate repositioning across two verticals that each carry structural demand characteristics: semiconductor materials and critical minerals. The proposed Ferrox merger gives SMTK a potential gateway into one of southern Africa's most significant undeveloped mineral deposits. Its TRUFLEX(R) materials continue generating commercial traction with some of the world's largest electronics manufacturers. What makes SMTK worth monitoring is the combination of scope and timing. Critical minerals are becoming a national security priority. Advanced semiconductor materials are increasingly vital in next-generation wearable and display technologies. Now official: coverage is a "Go" on Smartkem, Inc. (Nasdaq: SMTK). Make sure to keep your eyes peeled for updates heading your way soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 08/26/2026 and ending on 08/26/2026 to publicly disseminate information about (SMTK:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (SMTK:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/smtk-vel4u/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice